Calcium‐activated potassium channels and endothelial dysfunction: therapeutic options?
- 17 February 2009
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 156 (4) , 545-562
- https://doi.org/10.1111/j.1476-5381.2009.00052.x
Abstract
The three subtypes of calcium‐activated potassium channels (KCa) of large, intermediate and small conductance (BKCa, IKCaand SKCa) are present in the vascular wall. In healthy arteries, BKCachannels are preferentially expressed in vascular smooth muscle cells, while IKCaand SKCaare preferentially located in endothelial cells. The activation of endothelial IKCaand SKCacontributes to nitric oxide (NO) generation and is required to elicit endothelium‐dependent hyperpolarizations. In the latter responses, the hyperpolarization of the smooth muscle cells is evoked either via electrical coupling through myo‐endothelial gap junctions or by potassium ions, which by accumulating in the intercellular space activate the inwardly rectifying potassium channel Kir2.1 and/or the Na+/K+‐ATPase. Additionally, endothelium‐derived factors such as cytochrome P450‐derived epoxyeicosatrienoic acids and under some circumstances NO, prostacyclin, lipoxygenase products and hydrogen peroxide (H2O2) hyperpolarize and relax the underlying smooth muscle cells by activating BKCa. In contrast, cytochrome P450‐derived 20‐hydroxyeicosatetraenoic acid and various endothelium‐derived contracting factors inhibit BKCa. Aging and cardiovascular diseases are associated with endothelial dysfunctions that can involve a decrease in NO bioavailability, alterations of EDHF‐mediated responses and/or enhanced production of endothelium‐derived contracting factors. Because potassium channels are involved in these endothelium‐dependent responses, activation of endothelial and/or smooth muscle KCacould prevent the occurrence of endothelial dysfunction. Therefore, direct activators of these potassium channels or compounds that regulate their activity or their expression may be of some therapeutic interest. Conversely, blockers of IKCamay prevent restenosis and that of BKCachannels sepsis‐dependent hypotension.Mandarin translation ofKeywords
This publication has 245 references indexed in Scilit:
- The expression and function of Ca2+‐sensing receptors in rat mesenteric artery; comparative studies using a model of type II diabetesBritish Journal of Pharmacology, 2008
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- Modulation by simvastatin of iberiotoxin‐sensitive, Ca2+‐activated K+ channels of porcine coronary artery smooth muscle cellsBritish Journal of Pharmacology, 2007
- Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+‐activated K+channelsBritish Journal of Pharmacology, 2007
- Effects of methyl β‐cyclodextrin on EDHF responses in pig and rat arteries; association between SKCa channels and caveolin‐rich domainsBritish Journal of Pharmacology, 2007
- Altered acetylcholine, bradykinin and cutaneous pressure‐induced vasodilation in mice lacking the TREK1 potassium channel: the endothelial linkEMBO Reports, 2007
- Combination of Ca2+‐activated K+ channel blockers inhibits acetylcholine‐evoked nitric oxide release in rat superior mesenteric arteryBritish Journal of Pharmacology, 2006
- Impaired small‐conductance Ca2+‐activated K+ channel‐dependent EDHF responses in Type II diabetic ZDF ratsBritish Journal of Pharmacology, 2006
- Endothelial dysfunction in diabetesBritish Journal of Pharmacology, 2000
- Pharmacological characterization of small‐conductance Ca2+‐activated K+ channels stably expressed in HEK 293 cellsBritish Journal of Pharmacology, 2000